Background. Pre-infarction unstable angina pectoris (UAP) can be considered ischemic preconditioning. The aim of this study was to compare short and long term outcomes in patients with or without pre-infarction UAP and ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). Methods. 593 patients with STEMI (388 without and 205 with UAP) were evaluated. Levels of biomarkers (troponin I, BNP, NT-ProBNP, neopterin, endoglin and pentraxin-3) at hospital admission and 24 h after STEMI onset were assessed. Echocardiography was undertaken on the fourth day after MI and after 12 months. The median follow-up was 37 months. Results. We found no significant differences in sex, age or risk factors for atherosclerosis between the UAP and non-UAP group. As the median time from the onset of chest pain to admission was significantly longer in the UAP group (228 min vs 258 min; P=0.009), we used a propensity score to obtain comparable matched groups for use in further analyses. The levels of NT-proBNP were significantly higher on admission and after 24 hours in the UAP group. Left ventricular functions according to invasive and echocardiographic parameters were entirely comparable at hospitalization and after 12 months. No differences were found in severity index of acute heart failure during hospitalization. The incidence of major acute coronary events during follow-up was comparable for the groups. Conclusions. In patients with STEMI treated with primary PCI, pre-infarction UAP has no beneficial clinical effect during hospitalization or during long-term follow-up.
INTRODUCTION
Short periods of ischemia have been described in large number of experimental and clinical studies as protecting myocardial cells against following sustained ischemia of the myocardium [1] [2] [3] . Unstable angina pectoris (UAP) preceding myocardial infarction (pre-infarction or prodromal angina pectoris) represents intermittent ischemic periods which could be considered as ischemic preconditioning. It has been demonstrated that pre-infarction UAP resulted in decrease in mortality, acute heart failure, arrhythmias and infarction size 4, 5 patients with pre-infarction UAP had better short 6 and long-term 7 outcomes compared to patients with an abrupt onset of myocardial infarction. The main limitation of most studies is that they have been performed in patients with acute myocardial infarction treated with thrombolysis.
There is currently no general consensus on the causes of the protective effects of pre-infarction UAP although certain pathophysiological mechanisms have been described. The mechanism of ischemic preconditioning is based on activation of specific receptors on the cardiomyocyte cell membrane such as adenosine A1 (ref. 8 ), bradykinin B2 (ref. 9 ), α1A-and β2-adrenoreceptors 10, 11 and δ-opioid receptors 12 . The signal transduction pathways downstream of the trigger are complex and involve multiple protein kinases, notably protein kinase C (ref. 13 ), protein kinase A (ref. 14 ), mitogen activated protein kinases 15 and reperfusion injury salvage kinases (RISK pathway) (ref. 16 ). A considerable role in the preconditioning is played by mitochondria. Mitochondrial K ATP channel modulation and prevention of mitochondrial pore transition protein (mPTP) opening reduces necrotic [17] [18] [19] and apoptotic 20 myocardial cell death. The final effects of preconditioning involve inhibition of Ca 2+ overload, glucose uptake, structural holding, anti-inflammation and anti-apoptosis effects 21 . In addition, some studies have found that ischemic preconditioning preserves the anatomic microvasculature and functional vascular reactivity, as well limiting the impairment of coronary arteriolar dilation, arteriolar injury and endothelial dysfunction 22 . Other mechanisms involve the formation of thrombi that are less resistant to fibrinolysis 4, 23 or spontaneous recanalization of the infarction artery upon pre-infarction angina 24 . Opening of thin-walled vascular channels that connect coronary arteries (coronary collaterals), caused by increased pressure resulting from subtotal occlusion has been also suggested as a cardioprotective effect of prodromal angina pectoris 25, 26 . Although the data in general suggest a protective role of prodromal angina, the clinical benefits in the groups of patients with STEMI treated with primary percutaneous coronary intervention are still under discussion.
The aim of the analysis was to compare laboratory and invasive parameters, hospital outcomes and long term prognosis including occurrence of death, re-infarction, stroke, hospitalization due to acute heart failure (AHF) and left ventricle function in a group of consecutive patients with ST elevation myocardial infarction (STEMI) with or without pre-infarction UAP who were treated with primary percutaneous coronary intervention (PCI).
METHODS

Study population
From November 2005 to October 2008 a total of 593 patients with STEMI referred for primary PCI and admitted to the Coronary Care Unit (CCU) of the Internal Cardiology Department of the University Hospital Brno were included in the study. All patients were of Caucasian origin. Standard recommended therapy including ACE inhibitors, beta-blockers and statins administered as soon as possible after primary PCI. Exclusion criteria were: age over 80 years, known or newly diagnosed malignancy, inflammatory or connective tissue disease, previously known LV dysfunction and estimated life expectancy < 1 year, refusal to sign informed consent or non-compliance, regional reasons (foreign citizens or distance from living place to the hospital of more than 100 km). Informed written consent was obtained from all subjects before participation in the trial. The study protocol complied with the latest Declaration of Helsinki and was approved by the local Ethics Committee of the Faculty Hospital Brno and by the Ethics Committee of Masaryk University in Brno.
The diagnosis of STEMI was made on the basis of the presence of MI symptoms, relevant ECG changes (ST-segment elevation at the J point in two contiguous leads ≥0.1 mV in all leads including V7-9, in leads V2-V3 ≥0.2 mV in men ≥40 years; ≥0.25 mV in men <40 years, or ≥0.15 mV in women or new LBBB) and elevation of troponin I as a marker of myocardial necrosis. Time from onset of chest pain to primary PCI was < 12 h. Pre-infarction UAP was defined as at least 1 occurrence of typical chest pain at rest within 7 days before the onset of MI. The time of the onset of myocardial infarction was defined as severe chest pain that did not subside spontaneously within 20 min.
The diagnosis of acute heart failure was made according to the clinical signs on admission and/or during hospitalization (Killip I-IV).
The study sample was divided into 2 groups according to the presence of pre-infarction UAP: patients without unstable angina pectoris (non-UAP group, n=388) and patients with unstable angina preceding acute myocardial infarction (UAP group, n=205).
Laboratory methods
Samples of venous blood for analyses of B type natriuretic peptide (BNP) and N-terminal pro B-type natriuretic peptide (NT-ProBNP) levels were drawn immediately upon hospital admission before primary PCI (sample 1). Blood samples were drawn again exactly at 24 h after the onset of chest pain (sample 2). Samples were centrifuged within 20 min in a refrigerated centrifuge, and the plasma and serum were stored at -80°C. Standard biochemical and haematological blood tests were done immediately on hospital admission before primary PCI and 24 h after the onset of chest pain (including Troponin-I ADSV, Abbott Laboratories, Abbott Park, USA). BNP was analyzed using the AxSYM BNP-Microparticle Enzyme Immunoassay (Abbott Laboratories, Abbott Park, USA). NT-ProBNP was analyzed using the Cobas E411 NT-proBNP Imunoassay Kit (Roche Diagnostics, Indianapolis). Neopterin concentrations were determined in duplicate by commercially available ELISA (IBL International GmbH, Germany) following the manufacturer's instructions. Analytical sensitivity was 0.7 nmol/L, and intra-and inter-assay CV% were <6% and < 9%, respectively. Plasma levels of Pentraxin-3 were measured by commercially available sandwich ELISA (R&D Systems Inc., MN, USA). The assay sensitivity was 25 pg/mL, intra-and inter-assay precisions were < 4.4% and < 6.0%, respectively. Plasma levels of endoglin were measured by commercially available sandwich ELISA (R&D Systems Inc., MN, USA). The assay sensitivity was 7 pg/mL, intra-and inter-assay precisions were < 3.2% and < 6.5%, respectively.
Echocardiography assessment
Echocardiography assessment was carried out during the index admission (3 rd -5 th day after MI onset) and the second one during the follow-up. LV end-systolic volume (ESV), LV end-diastolic volume (EDV), and LV ejection fraction (EF) were mostly estimated using the bi-planar Simpson´s rule from apical two-and four-chamber views (90 % of values). The other values were determined using Teichholtz formula. EDV and ESV were indexed to body surface area. Echocardiography was assessed using Vivid 7 (GE Vingmed Ultrasound).
Invasive measurement
Invasive intra-aortic systolic blood pressure (SBP) and diastolic blood pressure (DBP), LVEDP and dP/dt/P were measured before left ventricle angiography using a fluidfilled catheter (5Fr pigtail catheter) in the supine position of the patients before primary PCI. Ejection fraction was determined by left ventricle angiography. Heart rate was recorded using electrocardiographic monitoring. A diseased coronary vessel was defined as the presence of at least one > 50% reduction of intraluminal diameter on major coronary arteries (left main, left anterior descending, left circumflex, right coronary arteries) or their branches with diameter ≥ 2.0 mm. Significant left main artery stenosis was coded as two-vessel disease.
Follow-up
Patients were prospectively monitored in the hospital cardiology outpatient department. Median follow-up was 37 months. The onset of death, myocardial re-infarction, stroke or hospitalization due to acute heart failure was included in the evaluation. The median follow-up to the last echocardiography and laboratory samples including natriuretic peptides was 12.2 months.
Statistical analysis
Standard descriptive statistics were applied; median and 5 th -95 th percentile range were used for continuous variables and absolute and relative frequencies for categorical variables. The statistical significance of differences between groups of patients was evaluated by Mann-Whitney U test for continuous variables and Fisher exact test for categorical variables. The statistical significance of differences among groups of patients was computed using the Kruskal-Wallis test, followed by post-hoc comparison of mean ranks. The survival of patients was described using the Kaplan-Meier survival curve and the comparison of groups of patients was computed using the log-rank test. Conside ring that the groups were not entirely comparable, the propensity score method was used to create two comparable matched groups according to the baseline characteristics.
RESULTS
A total of 593 patients were enrolled in the analysis and 205 of them had pre-infarction UAP. Baseline characteristics are shown in Table 1 . No significant differences in baseline characteristics were found for the two groups excluding the median time from the onset of chest pain to admission to the CCU, which was statistically significantly longer in the UAP group. As 30 min of the longer delay in the UAP group could play a clinically significant role, which could diminish positive effect of previous UAP, we used a propensity score to obtain comparable groups. After matching the groups, the delay to admission to the CCU was comparable in both groups ( Table 1) .
The laboratory findings for the matched groups are shown in Table 2 . The difference in the laboratory findings in the matched groups was significantly higher levels of NT-proBNP in UAP-group at admission as well as over 24 h after MI onset. Prognostic biomarkers neopterin and endoglin were comparable within both groups; pentraxin-3 level in UAP group was significantly lower after 24 h.
Invasive and echocardiography parameters are presented in Table 3 and we found no statistically significant differences in either invasive or echocardiography parameters between the matched groups.
The hospitalization course was comparable in both matched groups. There was no statistical difference in the occurrence of acute heart failure (nonUAP vs UAP group 28.6% vs 25.9%; P=NS) or its severity.
We found no differences in EF or left ventricle volumes during follow-up (Table 3) .
The median follow-up of patients was 37 months. No differences in the occurrence of the separate endpoints or composite endpoints of death, hospitalisation due to AHF, re-infarction and stroke were detected during the follow between the matched groups with or without preinfarction UAP. The long-term survival and occurrence of all monitored cardiovascular events are shown in Fig. 1 .
DISCUSSION
The results of this prospective study on patients with STEMI treated by primary PCI showed no differences in acute heart failure rate, invasive or echocardiographic parameters of left ventricle dysfunction or long term prognosis for patients with pre-infarction UAP and those without. Due to clinically significantly longer time from the onset of chest pain to primary PCI in the UAP group which could mask the protective effect of pre-infarction instability, we adopted a propensity score method to obtain two well matched groups with and without pre-infarction UAP.
As in the unmatched data, we found no protective effect of pre-infarction UAP in the matched groups. Based on evaluation of prognostic biomarker analysis within the UAP group there was only a non-significant trend to lower levels of troponin I as a marker of myocardial necrosis, slightly higher levels of NT-proBNP on admission and after 24 h (but not for BNP) and slightly lower level of pentraxin-3 after 24 h as a marker of inflammation. Levels of other new prognostic biomarkers after ACS -neopterin and endoglin were comparable for both groups.
Our data do not support the hypothesis that pre-infarction angina has a protective role.
In comparison with previous studies, the influence of pre-infarction angina was assessed for the first time in a large population of patients with STEMI treated with primary PCI followed-up prospectively on a long-term basis. Most of the previous clinical studies on pre-infarction UAP were performed in the time of thrombolytic treatment of myocardial infarction [4] [5] [6] [7] 23, 27, 28 . Ishihara et al. reported that prodromal angina 24 h before infarction was associated with a more frequent patent infarct-related coronary artery before reperfusion therapy (34% vs. 22%, P=0.03) and with reperfusion after thrombolytic therapy (80% vs. 60%, P=0.002) (ref. 29 ). This could be explained by faster dissolution of the thrombus in the presence of pre-infarction angina. Przyklenk et al. suggested in their experimental study that a short period of ischemia enhances the thrombolysis by induction of recombinant tissue plasminogen 30 . In patients treated by primary PCI, prodromal UAP was not associated with any significant differences between groups with/without pre-infarction UAP with respect to the patency of the infarct-related artery (TIMI-3 flow) either before the procedure (2.2% vs. 0%, P=1.0) or after it (84.8% vs. 84.4%, P=1.0) (ref. 31 ). The effect of pre-infarction UAPs in patients with acute myocardial infarction treated with primary PCI was evaluated only for hospitalization outcomes or a 30-day follow up so far 32, 33 ; our results provide information about long-term follow-up for the first time.
Evidence for the prognostic significance of pre-infarction UAP in the era of aggressive STEMI PCI treatment 34 is controversial. Although some studies have described better outcome in patients with pre-infarction UAP (ref. 35 ), in other studies no differences in the levels of cardiac enzymes -CKMB or troponin I (ref. 31, 36 ) or infarct size measured by 99mTc sestamibi 37 were found. In our study, there were no differences in the infarction size measured by the levels of troponin I in the groups with and without preinfarction angina (44 ng/mL vs. 48.8 ng/ mL, P=NS).
Recently Lorgis et al. suggested a beneficial effect of pre-infarction angina on short-term outcomes, especially ventricular arrhythmias and infarct size in NSTEMI pa- 38 . This beneficial effect is less apparent in patients with CV risk factors (hypertension, obesity), or under chronic use of CV drugs such as aspirin or nitrates. This implies that prior treatment may also modify the disease process and clinical presentation. Nitroglycerin has a cardioprotective effect against ischemia through a protein kinase C-dependent pathway which is also one of the mediators in the preconditioning process 39, 40 . We found significantly higher levels of NT-proBNP, especially on admission, in patients with pre-infarction UAP. It is known that ischemia triggers the release of natriuretic peptides 41 . As we found no differences in other parameters associated with acute heart failure or left ventricular dysfunction (ejection fraction, left ventricular end-diastolic pressure, end-diastolic and end-systolic volume - Table 3 ), we assume that the higher levels of NT-proBNP in patients with pre-infarction UAP were caused predominantly by previous ischemic insult.
Neopterin is a marker of macrophage activation with a putative physiological role in enhancing macrophage cytotoxicity. It was demonstrated that elevated levels are an independent prognostic markers of death, recurrent acute coronary syndrome and heart failure hospitalization after ACS (ref. 42, 43 ). We found no influence of pre-infarction UAP on neopterin levels which corresponds with similar long-term prognosis of both groups irrespective of prodromal angina.
Endoglin is a proliferation-associated and hypoxia-inducible glycoprotein expressed in endothelial cells. The level of endoglin decreases after MI and early endoglin decrease is an independent predictor of short term mortality 44 . We found no influence of pre-infarction UAP on levels of endoglin.
Pentraxin-3 is a long pentraxin, a marker of vascular inflammation 45 such as the short pentraxin C-reactive protein. Pentraxin-3 has been shown to be an independent prognostic marker of 3-month mortality in patients with STEMI (ref. 46 ). We found no difference in level of pentraxin-3 on admission but only slightly higher level of pentraxin-3 in patients without UAP after matching. This result could suggest that prodromal angina may result in milder inflammation reaction in patients with pre-infarction UAP but without influence on clinical outcomes.
Limitations
Although the number of patients here was sufficient for evaluating the clinical significance of prodromal UAP in an unselected cohort, assessment of the effect of UAP was not possible in various subgroups of patients, for example according to duration of prodromal chest pain, repeated chest pain, age or co-morbidities such as diabetes mellitus. For this reason, a larger sample of patients could provide more information. Another limitation of this study is that the diagnosis of ischemia was based on patient reported symptoms only.
CONCLUSION
In patients with ST elevation MI treated with primary PCI, pre-infarction UAP does not have a beneficial effect concerning acute heart failure occurrence, left ventricular function and the incidence of cardiovascular end-points during the long-term follow-up. There is a minimal effect of the pre-infarction UAP on the level of novel prognostic biomarkers such as neopterin, endoglin or pentraxin-3. Prodromal angina increases levels of NT-proBNP at admission and 24 h after; the mechanism is probably previous ischemic insult. There is alarming high percentage of patients with symptoms of prodromal unstable angina pectoris who are admitted into the hospital at the stage of myocardial infarction with ST elevation.
